PD-L1検査市場：市場規模 - セグメント別、シェア、規制、償還、2036年までの予測

プログラム細胞死リガンド 1（PD-L1）は腫瘍細胞に見られるタンパク質です。PD-L1の高発現は、免疫系ががん細胞を攻撃する際に本来の効果を発揮しないため、より攻撃的で急速に増殖するがんと関連しています。

PD-L1はPD-L1（免疫T細胞上に存在）と相互作用し、通常がん細胞とT細胞の間で起こるはずの免疫反応を不活性化します。PD-L1の発現は、無発現（0％）、低発現（1～49％）、高発現（50％以上）に分類されます。免疫療法はPD-L1が高発現している場合に使用されることが最も多いですが、他の治療法が無効な症例では、腫瘍検体中に1％以上の発現がある場合に免疫療法薬が使用されることもあります。PD-L1を高発現している腫瘍は、がん治療のための免疫療法薬の候補となります。

当レポートは、世界のPD-L1検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2036年までの市場予測、地域、国別の動向などを提供しています。

目次

現在上市されているPD-L1検査と競合情勢

• 主要な業界動向の洞察
• PD-L1検査のセグメント別総市場収益と2015年～2036年の市場展望
• セグメント別の手技総数、台数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• PD-L1検査市場のSWOT分析
• PD-L1検査市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

PD-L1 Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036 is built to visualize quantitative and qualitative market trends within In-Vitro Diagnostics Devices therapeutic area.

Programmed death ligand-1 (PD-L1) is a protein found on tumor cells. High expression of PD-L1 is linked to more aggressive and fast-growing cancers due to the immune system not being as effective as it should be in attacking cancer cells.

PD-L1 interacts with PD-L1 (found on immune T-cells) to deactivate the immune response that would normally occur between cancer cells and T-cells. PD-L1 expression is categorized by no expression (0%), low expression (1-49%) and high expression (50+%). Immunotherapy is most often used when PD-L1 expression is high; however, in some cases where other treatment options fail, immunotherapy medications are used when there is over 1% expression in the tumor sample. Tumors expressing high levels of PD-L1 are candidates for immunotherapy medications to treat cancer.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed PD-L1 Tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total PD-L1 Tests market revenue by segment and market outlooks from 2015-2036.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for PD-L1 Tests market.
• Competitive dynamics insights and trends provided for PD-L1 Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Amoy Diagnostics Co Ltd, BioGenex Laboratories.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the PD-L1 Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving PD-L1 Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PD-L1 Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific PD-L1 Tests market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.